[Managing the discontinuation of GLP-1 agonists : how to insure a smooth transition].

Rev Med Suisse

Unité d'éducation thérapeutique du patient, Centre collaborateur OMS, Service de médecine de premier recours, Hôpitaux universitaires de Genève, 1211 Genève 14.

Published: March 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Glucagon-like peptide-1 receptor agonists have revolutionized the management of obesity. However, when they are discontinued, often due to reimbursement limitations, there is a high risk of weight regain. This is linked to complex biological mechanisms, including hormonal disruption, a drop in basal metabolism, and dysregulation of central reward circuits. Lasting weight loss is best achieved through a gradual transition, accompanied by professional and interdisciplinary follow-up that includes nutritional, psychological, and behavioral interventions, as well as adapted physical activity. A comprehensive approach based on therapeutic patient education is essential for maintaining long-term therapeutic benefits and preventing rebound effects.

Download full-text PDF

Source
http://dx.doi.org/10.53738/REVMED.2025.21.910.527DOI Listing

Publication Analysis

Top Keywords

[managing discontinuation
4
discontinuation glp-1
4
glp-1 agonists
4
agonists insure
4
insure smooth
4
smooth transition]
4
transition] glucagon-like
4
glucagon-like peptide-1
4
peptide-1 receptor
4
receptor agonists
4

Similar Publications

In wheat allergy dependent on augmentation factors (WALDA), allergic reactions occur when wheat ingestion is combined with exercise or rarely other augmentation factors. We analyzed clinical characteristics and disease burden in recreationally active and trained individuals with WALDA diagnosed by oral challenge test. Clinical characteristics, serological data, and quality of life (QOL) questionnaires were analyzed and completed with follow-up interviews.

View Article and Find Full Text PDF

Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.

View Article and Find Full Text PDF

Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.

Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.

View Article and Find Full Text PDF

Background: Invasive central nervous system (CNS) aspergillosis is rare among human immunodeficiency virus (HIV)-positive patients due to preserved neutrophil function, despite significant CD4+ T-cell depletion. Diagnosis typically requires histopathologic confirmation, but polymerase chain reaction (PCR) testing has introduced new challenges due to its high sensitivity but limited specificity.

Case Presentation: We describe a newly diagnosed 43-year-old HIV-positive male with concurrent Hodgkin lymphoma who presented with progressive neurological decline and a ring-enhancing brain lesion.

View Article and Find Full Text PDF

Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.

View Article and Find Full Text PDF